Atlanta, GA25 Active Studies

Heart Attack Clinical Trials in Atlanta, GA

Find 25 actively recruiting heart attack clinical trials in Atlanta, GA. Connect with local research sites and explore new treatment options.

25
Active Trials
23
Sponsors
8,260
Enrolling

Recruiting Heart Attack Studies in Atlanta

RecruitingAtlanta, GANCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)."...

2,000 participants
Beat AML, LLC
View Study Details
RecruitingAtlanta, GANCT03037164

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Stage A: To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBC...

800 participants
Cerus Corporation
View Study Details
RecruitingAtlanta, GANCT06876649

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib....

787 participants
Eli Lilly and Company
View Study Details
RecruitingAtlanta, GANCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

572 participants
Incyte Corporation
View Study Details
RecruitingAtlanta, GANCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

413 participants
Syndax Pharmaceuticals
View Study Details
RecruitingAtlanta, GANCT04278768

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Sy...

366 participants
Curis, Inc.
View Study Details
RecruitingAtlanta, GANCT05429632

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

366 participants
Priothera SAS
View Study Details
RecruitingAtlanta, GANCT07102459

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

The goal of this clinical trial is to learn if LTG-001 works to treat post-operative / acute pain after an abdominoplasty procedure. It will also learn more information on the safety of LTG-001. The ...

360 participants
Latigo Biotherapeutics
View Study Details
RecruitingAtlanta, GANCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

279 participants
Eli Lilly and Company
View Study Details
RecruitingAtlanta, GANCT06846671

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venet...

250 participants
BeiGene
View Study Details
RecruitingAtlanta, GANCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

240 participants
Etan Orgel
View Study Details
RecruitingAtlanta, GANCT03850574

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

240 participants
Aptose Biosciences Inc.
View Study Details
RecruitingAtlanta, GANCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

236 participants
Taiho Oncology, Inc.
View Study Details
RecruitingAtlanta, GANCT06559163

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE)....

190 participants
Zenas BioPharma (USA), LLC
View Study Details
RecruitingAtlanta, GANCT05292339

Ketorolac in Upper Extremity Tendinopathy and Arthropathy

Osteoarthritis (OA) and inflammatory conditions of the tendons and joints of the shoulder, elbow, hand, and wrist are common yet disabling diseases. Standard management utilizes conservative measures ...

160 participants
Emory University
View Study Details
RecruitingAtlanta, GANCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

142 participants
AstraZeneca
View Study Details
RecruitingAtlanta, GANCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Asso...

140 participants
Cogent Biosciences, Inc.
View Study Details
RecruitingAtlanta, GANCT03813407

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate...

140 participants
AstraZeneca
View Study Details
RecruitingAtlanta, GANCT06055439

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

135 participants
Chimeric Therapeutics
View Study Details
RecruitingAtlanta, GANCT06340451

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approxim...

132 participants
Pacira Pharmaceuticals, Inc
View Study Details
RecruitingAtlanta, GANCT07116499

A Study of K-645 in the Treatment of Multiple Migraine Attacks

This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patient...

120 participants
Kallyope Inc.
View Study Details
RecruitingAtlanta, GANCT02323399

Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV

The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population...

100 participants
West-Ward Pharmaceutical
View Study Details
RecruitingAtlanta, GANCT06517641

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated....

60 participants
Medical College of Wisconsin
View Study Details
RecruitingAtlanta, GANCT02828592

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients...

20 participants
Northside Hospital, Inc.
View Study Details
RecruitingAtlanta, GANCT06121297

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...

12 participants
Cabaletta Bio
View Study Details

About Heart Attack Clinical Trials in Atlanta

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 25 heart attack clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 8,260 participants. Research is being sponsored by Beat AML, LLC, Cerus Corporation, Eli Lilly and Company and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Atlanta — FAQ

Are there heart attack clinical trials in Atlanta?

Yes, there are 25 heart attack clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 25 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated March 2, 2026 from ClinicalTrials.gov